Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of May 2015, with the report dated May 21, 2015. The filing addresses a material change in corporate governance involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of board composition changes and contains no financial performance data.
Material Changes
- Director Departure: Rami Epstein retired from the Board of Directors and the audit and compensation committees effective May 20, 2015.
- Reason for Departure: The retirement was necessitated by a new interpretation of Israeli law by the Israel Securities Authority (ISA) received on May 17, 2015. The ruling states that an "unaffiliated director" cannot serve for a term extending beyond nine years. Mr. Epstein had served since May 2006.
- Director Appointment: Michal Marom Brikman was appointed to the Board on May 20, 2015, to fill the vacancy. She will also serve on the audit and compensation committees.
- New Director Background: Ms. Brikman is a certified public accountant in Israel (since 1994), holds an M.A. in business and an M.S.F., and currently serves as CFO of Linkury Ltd. She is deemed independent under NASDAQ rules and Rule 10A-3(b)(1).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to regulatory compliance with Israeli corporate governance laws regarding director tenure limits.
Key Facts for Investor Verification
- Verify the independence status and potential conflicts of interest for the newly appointed director, Michal Marom Brikman, given her roles on multiple other Israeli public company boards.
- Confirm the impact of the ISA's interpretation of the nine-year term limit for unaffiliated directors on the stability of the Board.
- Note that this filing contains no financial data; investors should refer to the most recent Form 20-F for financial performance.